Association Between Inflammatory Pathways and Phenotypes of Pulmonary Dysfunction Using Cluster Analysis in Persons Living With HIV and HIV-Uninfected Individuals.
Adult
CD4 Lymphocyte Count
Carbon Monoxide
Cluster Analysis
Cohort Studies
Female
HIV Infections
/ complications
Humans
Lung
/ physiopathology
Lung Diseases
/ complications
Male
Middle Aged
Phenotype
Pulmonary Disease, Chronic Obstructive
/ physiopathology
Pulmonary Emphysema
Respiratory Function Tests
Risk Factors
Th1 Cells
Th17 Cells
Th2 Cells
United States
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 02 2020
01 02 2020
Historique:
entrez:
14
1
2020
pubmed:
14
1
2020
medline:
27
6
2020
Statut:
ppublish
Résumé
Persons living with HIV (PLWH) are at risk of developing different phenotypes of chronic lung disease, including chronic obstructive pulmonary disease. Mechanisms underlying these phenotypes are unclear. To identify clusters of peripheral inflammatory mediators associated with pulmonary function to determine inflammatory pathways and phenotypes of chronic obstructive pulmonary disease in PLWH and HIV-uninfected individuals. Study participants were PLWH and HIV-uninfected individuals enrolled in the Pittsburgh HIV Lung Cohort. Pulmonary function tests were performed for all participants. Chest computed tomographic scans were performed in a subset of PLWH. Plasma levels of 19 inflammatory mediators were measured by Luminex or ELISA. Clusters were identified based on the expression pattern of inflammatory mediators in PLWH and HIV-uninfected individuals, and the relationships among clinical parameters were evaluated within clusters by using cluster and network analyses. In PLWH, we identified a distinct cluster with higher levels of Th1, Th2, and Th17 inflammatory mediators with increased complexity of these mediators and inferred presence of pathogenic Th17 cell types. Individuals in this cluster had worse airway obstruction and more radiographic emphysema. In HIV-uninfected individuals, a cluster with high-grade systemic inflammation also had worse diffusing capacity for carbon monoxide. Inflammatory pathways associated with pulmonary dysfunction in PLWH suggest multifaceted immune dysregulation involved in different phenotypes of pulmonary dysfunction with a potential specific contribution of the Th17 pathway to airway obstruction in PLWH. Identification of these associations may help in development of treatments that could alter the course of the disease.
Sections du résumé
BACKGROUND
Persons living with HIV (PLWH) are at risk of developing different phenotypes of chronic lung disease, including chronic obstructive pulmonary disease. Mechanisms underlying these phenotypes are unclear.
OBJECTIVE
To identify clusters of peripheral inflammatory mediators associated with pulmonary function to determine inflammatory pathways and phenotypes of chronic obstructive pulmonary disease in PLWH and HIV-uninfected individuals.
METHODS
Study participants were PLWH and HIV-uninfected individuals enrolled in the Pittsburgh HIV Lung Cohort. Pulmonary function tests were performed for all participants. Chest computed tomographic scans were performed in a subset of PLWH. Plasma levels of 19 inflammatory mediators were measured by Luminex or ELISA. Clusters were identified based on the expression pattern of inflammatory mediators in PLWH and HIV-uninfected individuals, and the relationships among clinical parameters were evaluated within clusters by using cluster and network analyses.
RESULTS
In PLWH, we identified a distinct cluster with higher levels of Th1, Th2, and Th17 inflammatory mediators with increased complexity of these mediators and inferred presence of pathogenic Th17 cell types. Individuals in this cluster had worse airway obstruction and more radiographic emphysema. In HIV-uninfected individuals, a cluster with high-grade systemic inflammation also had worse diffusing capacity for carbon monoxide.
CONCLUSIONS
Inflammatory pathways associated with pulmonary dysfunction in PLWH suggest multifaceted immune dysregulation involved in different phenotypes of pulmonary dysfunction with a potential specific contribution of the Th17 pathway to airway obstruction in PLWH. Identification of these associations may help in development of treatments that could alter the course of the disease.
Identifiants
pubmed: 31929407
doi: 10.1097/QAI.0000000000002234
pii: 00126334-202002010-00013
pmc: PMC7193693
mid: NIHMS1549535
doi:
Substances chimiques
Carbon Monoxide
7U1EE4V452
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
189-196Subventions
Organisme : NIAID NIH HHS
ID : U01 AI035041
Pays : United States
Organisme : NCI NIH HHS
ID : K08 CA230170
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035043
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035040
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI034993
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL123342
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035042
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR025005
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI031834
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035004
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA190158
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024131
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI034989
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI034994
Pays : United States
Organisme : NHLBI NIH HHS
ID : K24 HL087713
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL138630
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI035039
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL125049
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL120398
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD032632
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI042590
Pays : United States
Références
Respir Physiol Neurobiol. 2011 Sep 30;178(3):395-405
pubmed: 21397052
Chest. 2015 Nov;148(5):1307-1322
pubmed: 26135024
Front Psychol. 2013 Jan 10;3:606
pubmed: 23335907
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
Nat Immunol. 2011 Jun;12(6):568-75
pubmed: 21516111
J Biol Chem. 2003 May 9;278(19):17036-43
pubmed: 12624114
Behav Sci. 1967 Mar;12(2):153-5
pubmed: 6030099
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
pubmed: 9872837
J Infect Dis. 2003 May 15;187(10):1534-43
pubmed: 12721933
Acad Radiol. 2003 Nov;10(11):1224-36
pubmed: 14626297
Nat Immunol. 2011 Jun;12(6):560-7
pubmed: 21516112
Crit Care Med. 2016 Nov;44(11):e1074-e1081
pubmed: 27513538
PLoS One. 2014 Oct 29;9(10):e109027
pubmed: 25354261
Mol Med. 2017 Jan;22:821-829
pubmed: 27900388
Nat Immunol. 2005 Nov;6(11):1133-41
pubmed: 16200068
AIDS. 2016 Jun 1;30(9):1327-39
pubmed: 26990629
Annu Rev Physiol. 2010;72:495-516
pubmed: 20148686
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):e23-e29
pubmed: 27716727
Thorax. 2000 Aug;55(8):631-2
pubmed: 10899236
Chest. 2006 Nov;130(5):1326-33
pubmed: 17099007
Chest. 2017 Nov;152(5):1053-1060
pubmed: 28427967
J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):137-47
pubmed: 19131896
Am J Respir Crit Care Med. 2013 Apr 1;187(7):728-35
pubmed: 23392440
J Stat Softw. 2018 Apr;84:
pubmed: 30450020
AIDS. 2014 Nov 13;28(17):2505-15
pubmed: 25574956
Am J Respir Crit Care Med. 1996 Feb;153(2):656-64
pubmed: 8564114
Am J Respir Crit Care Med. 2010 Sep 15;182(6):790-6
pubmed: 20522793
Eur Respir J. 2005 Oct;26(4):720-35
pubmed: 16204605
J Infect Dis. 1999 Apr;179(4):859-70
pubmed: 10068581
J Inflamm Res. 2018 Apr 24;11:155-167
pubmed: 29731655
Med Phys. 2007 Jul;34(7):2844-52
pubmed: 17821992
HIV Med. 2014 Jul;15(6):321-9
pubmed: 24314004
Am J Respir Crit Care Med. 2011 Feb 1;183(3):388-95
pubmed: 20851926
Cardiovasc Res. 2007 Oct 1;76(1):8-18
pubmed: 17617392
PLoS One. 2013 Dec 03;8(12):e79804
pubmed: 24312451
J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):271-8
pubmed: 23979001
PLoS One. 2016 Jan 11;11(1):e0146355
pubmed: 26752193
Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):612-6
pubmed: 10934095
Endocrine. 2016 Apr;52(1):30-8
pubmed: 26475497
AIDS. 2012 Mar 27;26(6):731-40
pubmed: 22210636
PLoS One. 2011 May 10;6(5):e19424
pubmed: 21573002
J Allergy Clin Immunol. 2014 Jun;133(6):1557-63.e5
pubmed: 24332216
Eur Respir J. 2012 Aug;40(2):495-6
pubmed: 22855468
Curr HIV/AIDS Rep. 2013 Mar;10(1):42-50
pubmed: 23079728
Am J Respir Crit Care Med. 2008 Jan 1;177(1):108-13
pubmed: 17932378
Curr HIV/AIDS Rep. 2010 Feb;7(1):4-10
pubmed: 20425052
Respir Res. 2010 Sep 10;11:122
pubmed: 20831787
Eur Respir J. 2010 Sep;36(3):531-9
pubmed: 20075045